BACKGROUND: Novel nicotine delivery products, such as electronic cigarettes (e-cigarettes), have dramatically grown in popularity despite limited data on safety and benefit. In contrast, the similar U.S. Food and Drug Administration (FDA)-approvednicotine inhaler is rarely utilized by smokers. Understanding this paradox could be helpful to determine the potential for e-cigarettes as an alternative to tobacco smoking. OBJECTIVE: To compare the e-cigarette with the nicotine inhaler in terms of perceived benefits, harms, appeal, and role in assisting with smoking cessation. DESIGN: A cross-over trial was conducted from 2012 to 2013 PARTICIPANTS/ INTERVENTIONS:Forty-one current smokers age 18 and older used the e-cigarette and nicotine inhaler each for 3 days, in random order, with a washout period in between. Thirty-eight participants provided data on product use, perceptions, and experiences. MAIN MEASURES: The Modified Cigarette Evaluation Questionnaire (mCEQ) measured satisfaction, reward, and aversion. Subjects were also asked about each product's helpfulness, similarity to cigarettes, acceptability, image, and effectiveness in quitting smoking. Cigarette use was also recorded during the product-use periods. KEY RESULTS: The e-cigarette had a higher total satisfaction score (13.9 vs. 6.8 [p < 0.001]; range for responses 3-21) and higher reward score (15.8 vs. 8.7 [p < 0.001]; range for responses 5-35) than the inhaler. The e-cigarette received higher ratings for helpfulness, acceptability, and "coolness." More subjects would use the e-cigarette to make a quit attempt (76 %) than the inhaler (24 %) (p < 0.001). Eighteen percent (7/38) of subjects abstained from smoking during the 3-day periods using the e-cigarette vs. 10 % (4/38) using the inhaler (p = 0.18). CONCLUSION: The e-cigarette was more acceptable, provided more satisfaction, and had higher perceived benefit than the inhaler during this trial. E-cigarettes have the potential to be important nicotine delivery products owing to their high acceptance and perceived benefit, but more data are needed to evaluate their actual efficacy and safety. Providers should be aware of these issues, as patients will increasingly inquire about them.
RCT Entities:
BACKGROUND: Novel nicotine delivery products, such as electronic cigarettes (e-cigarettes), have dramatically grown in popularity despite limited data on safety and benefit. In contrast, the similar U.S. Food and Drug Administration (FDA)-approved nicotine inhaler is rarely utilized by smokers. Understanding this paradox could be helpful to determine the potential for e-cigarettes as an alternative to tobacco smoking. OBJECTIVE: To compare the e-cigarette with the nicotine inhaler in terms of perceived benefits, harms, appeal, and role in assisting with smoking cessation. DESIGN: A cross-over trial was conducted from 2012 to 2013 PARTICIPANTS/ INTERVENTIONS: Forty-one current smokers age 18 and older used the e-cigarette and nicotine inhaler each for 3 days, in random order, with a washout period in between. Thirty-eight participants provided data on product use, perceptions, and experiences. MAIN MEASURES: The Modified Cigarette Evaluation Questionnaire (mCEQ) measured satisfaction, reward, and aversion. Subjects were also asked about each product's helpfulness, similarity to cigarettes, acceptability, image, and effectiveness in quitting smoking. Cigarette use was also recorded during the product-use periods. KEY RESULTS: The e-cigarette had a higher total satisfaction score (13.9 vs. 6.8 [p < 0.001]; range for responses 3-21) and higher reward score (15.8 vs. 8.7 [p < 0.001]; range for responses 5-35) than the inhaler. The e-cigarette received higher ratings for helpfulness, acceptability, and "coolness." More subjects would use the e-cigarette to make a quit attempt (76 %) than the inhaler (24 %) (p < 0.001). Eighteen percent (7/38) of subjects abstained from smoking during the 3-day periods using the e-cigarette vs. 10 % (4/38) using the inhaler (p = 0.18). CONCLUSION: The e-cigarette was more acceptable, provided more satisfaction, and had higher perceived benefit than the inhaler during this trial. E-cigarettes have the potential to be important nicotine delivery products owing to their high acceptance and perceived benefit, but more data are needed to evaluate their actual efficacy and safety. Providers should be aware of these issues, as patients will increasingly inquire about them.
Authors: Joseph C Cappelleri; Andrew G Bushmakin; Christine L Baker; Elizabeth Merikle; Abayomi O Olufade; David G Gilbert Journal: Addict Behav Date: 2006-07-27 Impact factor: 3.913
Authors: Michael B Steinberg; Ayse Akincigil; Cristine D Delnevo; Stephen Crystal; Jeffrey L Carson Journal: Am J Prev Med Date: 2006-03-23 Impact factor: 5.043
Authors: Cheryl L Perry; MeLisa R Creamer; Benjamin W Chaffee; Jennifer B Unger; Erin L Sutfin; Grace Kong; Ce Shang; Stephanie L Clendennen; Suchitra Krishnan-Sarin; Mary Ann Pentz Journal: Nicotine Tob Res Date: 2020-06-12 Impact factor: 4.244
Authors: Matthew J Carpenter; Bryan W Heckman; Amy E Wahlquist; Theodore L Wagener; Maciej L Goniewicz; Kevin M Gray; Brett Froeliger; K Michael Cummings Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-10 Impact factor: 4.254
Authors: Cheryl Oncken; Ellen A Dornelas; Chia-Ling Kuo; Heather Z Sankey; Henry R Kranzler; Erin L Mead; Ms Sheila D Thurlow Journal: Am J Obstet Gynecol MFM Date: 2019-03-27